RESEARCH TRIANGLE PARK – Fennec Pharmaceuticals released compensation details for its newly created chief commercial officer position, according to a Securities and Exchange Commission filing.

Shubh Goel’s initial base salary will be $360,000 annually in her new role, with a yearly 40 percent discretionary salary bonus and an option to acquire 175,000 of Fennec common stock.


As chief commercial officer, Goel will oversee Fennec’s commercial strategy and organization, including the launch and commercialization of PEDMARK, the company’s primary product.

PEDMARK is an investigational drug designed to protect pediatric chemotherapy patients against hearing loss. The drug is currently pending approval by the Food and Drug Administration.

Prior to joining the Research Triangle Park-based pharmaceutical maker, Goel most recently served as vice president of commercial strategy and operations at Odonate Therapeutics. Goel has nearly 20 years of experience in marketing and launching of oncology-related products.

Chief Executive Officer Rosty Raykov said Goel’s experience will be instrumental in preparing for the launch of PEDMARK.

“We are excited to have Shubh join Fennec as she brings significant commercial and oncology experience in the U.S. and globally,” Raykov said.

Shares of Fennec were trading at $4.82 Thursday afternoon, up 5 cents.

This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism.